Publications for Abela, I A
|Up a level|
Abela, Irene A; Scherrer, Alexandra U; Böni, Jürg; Yerly, Sabine; Klimkait, Thomas; Perreau, Matthieu; Hirsch, Hans H; Furrer, Hansjakob; Calmy, Alexandra; Schmid, Patrick; Cavassini, Matthias; Bernasconi, Enos; Günthard, Huldrych F; Swiss HIV Cohort Study (2019). Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients. Clinical Infectious Diseases:Epub ahead of print.
Abela, Irene A; Murer, Christian; Schuurmans, Macé M; Schmitt, Juergen W; Muller, Frabci; Imkamp, Frank; Mueller, Nicolas J; Benden, Christian (2018). A cluster of scedosporiosis in lung transplant candidates and recipients: the Zurich experience and review of the literature. Transplant Infectious Disease, 20(1):e12792.
Abela, Irene A; Berlinger, Livia; Schanz, Merle; Reynell, Lucy; Günthard, Huldrych F; Rusert, Peter; Trkola, Alexandra (2012). Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathogens, 8(4):e1002634.
Abela, Irene Alma. The role of neutralizing antibodies in HIV infection. 2012, University of Zurich, Faculty of Science.
Abela, Irene A. The role of neutralizing antibodies in inhibition of cell-cell transmission. 2012, University of Zurich, Faculty of Science.
Ruprecht, C R; Krarup, A; Reynell, L; Mann, A M; Brandenberg, O F; Berlinger, L; Abela, I A; Regoes, R R; Günthard, H F; Rusert, P; Trkola, A (2011). MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. Journal of Experimental Medicine, 208(3):439-454.
Abela, I A; Reynell, L; Trkola, A (2010). Therapeutic antibodies in HIV treatment - classical approaches to novel advances. Current Pharmaceutical Design, 16(33):3754-3766.
Abela, I A. Isolation of human monoclonal antibody recognizing tumor-associated antigen NY-ESO-1 on tissue sections. 2009, University of Zurich, Faculty of Medicine.